

Assessing the Performance of Software in Measuring Tumor Change:

The Biochange Challenge Problem

Dr. Charles Fenimore

Team: Brian Antonishek, Dr. John Lu, Dr. Jonathon Phillips

Biochange '08 Webpage

<http://www.itl.nist.gov/iad/894.05/biochange2008/Biochange2008-webpage.htm>



Lesion size/change in Clinical CT

- ⊕ Today: measuring change in medical images is unreliable.
 - ⊕ Leading measure of lesion size in medical imagery is the (lineal) span. Lesion change is measured by comparing the spans.
- ⊕ Future: measure change using volume, mass, or other biomarkers.

Scan 1


Patient 23

Scan 2



Lesion size/change hazards

- ✦ RECIST measure in **RED**. Change fraction = $L_2/L_1 - 1 = -5\%$
- ✦ Volume change (of white blob) consensus = $V_2/V_1 - 1 = -29\%$
- ✦ Disease progression or response to therapy can be masked by high levels of uncertainty.



Key goals of benchmarking

Broad goal: Support the development of reliable software and methods for medical imaging measurements.


Specific problem: Assess methods for performance assessment of software – in this case for change analysis of lesions in lung CT.

Elements of Benchmarking for Change Analysis Algorithms

Evaluation Materials:

Image Collections by Academics, Government,
Pharma, RSNA, etc,

Curation/metadata developed.



**publicly available
Image data set**



Participants run their change analysis
software or algorithms on data and
report results to NIST

Performance Analysis

- Exploratory data analysis, analysis of sources of variation and bias: comparison between algorithms, comparison with markup.
- Big question: Is reliable ground truth available?



Challenge Problems for Change Analysis Software & Algorithms

Benchmarking challenges: NIST & Cornell

Biochange 2008 – Pilot study

Volcano '09 – focus on lung cancer screening

Biochange 2009 – response to therapy in stage 3
& 4 lung cancer.

Standards: work with algorithm developers
and radiologists. NIST & other government,
RSNA, ACR, . . .

Technology Applications

- ❖ Impact of high unreliability/uncertainty.
 - Pharmaceutical trials are longer than they would be with accurate, reliable measures.
 - Patient response to therapy is measured in units of weeks and months instead of days.

Commercial Applications

- ❖ Improved radiology process enhances:
 - ❖ drug trials – faster
 - ❖ individual patient's response to therapy - measured in shorter times.
 - ❖ more effective therapy

Collaboration Opportunities

Download and run on the BC '08 Pilot Study data.

Participate in BC '09 when announced 10/09

- ✚ NIST provides access to CT lung data, each case has a pair of CT scans with identification of regions of interest.
- ✚ Participants run their change analysis software on the data & report results.
- ✚ NIST analyzes the performance of software / algorithms against markup.